Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available.
Imagion Biosystems Limited has announced significant progress in its MagSense® HER2 Breast Cancer diagnostic imaging program, with the commencement of manufacturing for the Phase 2 clinical trial. The company has also secured $3.5 million in funding and appointed Dr. Nina Webster as a Non-Executive Director to strengthen its leadership team. Additionally, Imagion has initiated a collaboration with Wayne State University to optimize imaging protocols, supported by Siemens Healthineers, which could enhance the diagnostic utility of its molecular MRI technology.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is a company focused on enhancing healthcare outcomes through early cancer detection using its proprietary MagSense® imaging technology.
Average Trading Volume: 5,060,608
Technical Sentiment Signal: Sell
Current Market Cap: A$3.94M
See more data about IBX stock on TipRanks’ Stock Analysis page.